MSD Animal Health Receives Marketing Authorization from European Commission for BRAVECTO™ (fluralaner)

Dateline City:

SUMMIT, N.J.

First Chewable Tablet Approved for Fleas and Ticks in Dogs Effective for 12 Weeks (8 Weeks for Rhipicephalus sanguineus Ticks)

SUMMIT, N.J.--(BUSINESS WIRE)--MSD Animal Health, known as Merck Animal Health in the United States and
Canada, announced today that following a positive opinion from the
Committee for Medicinal Products for Veterinary Use (CVMP), the European
Commission has granted marketing authorization for the veterinary
medicinal product BRAVECTO™ (fluralaner) chewable tablets for dogs
(112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg).
Language:

English

Contact:

Media:MSD Animal HealthAmy Firsching, [phone]orPam Eisele, [phone]

Ticker Slug:

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Corporate News - February 17, 2014 Category: Pharmaceuticals Tags: Corporate News Animal Health Latest News Source Type: news